maintenance hemodialysis patients witn osteoporosis
Conditions
Interventions
denosumab combined with conventional treatment group:denosumab injection 60mg, injected subcutaneously every six months
conventional treatment group:coutinue with the original therapeutic schedule
Sponsors
The Third Affiliated Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1)Voluntarily sign informed consent.2) Age 18-80.3) Regular maintenance hemodialysis for at least 3 months with any of the following three criteria: hip or vertebral fragility fracture; Bone mineral density of axial bone or bone mineral density of distal 1/3 of radius was evaluated by dual-energy X-ray densitometry (DXA) with T value=-2.5; Bone density measurements were consistent with reduced bone mass and a brittle fracture of the proximal humerus, pelvis, or distal forearm.
Exclusion criteria
Exclusion criteria: 1) Those who have contraindicated the use of denosumab. 2) Patients who have used anti-osteoporosis drugs such as bisphosphonates and denosumab in the past 6 months. 3)iPTH< 150pg/ml. 4) Corrected calcium<8.4mg/dL. 5) Patients with cancer, severe liver insufficiency, serious heart disease including coronary heart disease, heart failure,and arrhythmia. 6) Fertile women who are not on contraception, pregnant or breastfeeding. 7) Any medical or surgical conditions not specified in the protocol that the investigator believes may pose a high risk to the patient or prevent the patient from complying with the study requirements or completing the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fracture; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vascular calcification and incidence of cardiovascular events; | — |
Countries
China
Contacts
Public ContactTANG YING
The Third Affiliated Hospital of Southern Medical University
Outcome results
None listed